What is a pleomorphic adenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a Pleomorphic Adenoma?

Pleomorphic adenoma is the most common benign salivary gland tumor, characterized by a mixed composition of epithelial, myoepithelial, and mesenchymal components enclosed by a fibrous capsule. 1, 2

Epidemiology and Clinical Presentation

  • Occurs most frequently in the 4th through 6th decades of life, with a female predominance (60% female, 40% male) 2
  • The parotid gland is the primary site in 70-76% of cases, followed by the submandibular gland (13-17%), minor salivary glands of the palate (7%), and rarely the lacrimal gland, lips, or nasal cavity 1, 2
  • Presents as a slowly progressive, painless swelling in 85% of cases, typically well-delineated and not involving the facial nerve 1, 2
  • When parotid tumors occur, 73% develop on the right side 1

Histopathological Features

  • Contains three distinct components: epithelial cells, myoepithelial cells, and mesenchymal stroma (myxochondroid matrix), separated from surrounding tissue by a fibrous capsule 2
  • Exhibits remarkable cytomorphological and architectural diversity, which gives the tumor its "pleomorphic" designation 3, 4
  • Signal intensity on imaging varies according to cellular density, proportion of epithelial versus stromal components, and stromal type 4

Diagnostic Approach

  • Fine-needle aspiration biopsy (FNAB) using the Milan System for Reporting Salivary Gland Cytopathology demonstrates 98.5% sensitivity and 99% specificity for detecting malignant parotid tumors, helping distinguish PA from malignancy 5
  • MRI with and without intravenous contrast is the preferred imaging modality when detailed surgical planning is required, showing suspicious features, or demonstrating growth 5
  • On T2-weighted MRI, typical pleomorphic adenomas show marked hyperintensity reflecting abundant myxochondroid stroma, with a hypointense rim indicating the fibrous capsule 4
  • CT with IV contrast serves as an alternative when MRI is contraindicated, though it provides inferior soft-tissue detail 5

Diagnostic Pitfalls and Challenging Features

Pseudoinvasive Features (22% of cases)

  • Satellite nodules (most common at 43.5%), capsular penetration, irregular growth patterns, pseudopodia, lipomatous changes, and vascular permeation can mimic malignant invasion 3

Pseudomalignant Cytomorphology (93% of cases)

  • Increased cellularity, cellular atypia, heightened proliferative activity, oncocytic metaplasia, and necrosis may suggest malignancy on histology 3

Mimicry of Defined Malignancies (29% of cases)

  • Can resemble myoepithelial carcinoma, adenoid cystic carcinoma, and polymorphous adenocarcinoma, requiring meticulous examination with immunohistochemical and molecular analyses 3, 6

Secondary Histological Changes

  • Fibrosis, lipometaplasia, ossification, cystic degeneration, and infarction occur rarely but complicate differential diagnosis 4

Immunohistochemical Profile

  • Positive markers include: calponin, CD9, GFAP, Mcl-2, NM23, p63, S-100, smooth muscle actin (SMA), and SOX10 2
  • PLAG1 (pleomorphic adenoma gene 1) is the diagnostic marker most frequently employed as it is specific for pleomorphic adenoma 2

Clinical Behavior and Malignant Potential

  • Despite being histologically benign, pleomorphic adenoma has a propensity to recur if incompletely excised and can undergo malignant transformation to carcinoma ex-pleomorphic adenoma 1, 2
  • Metastatic pleomorphic adenoma (MPA) is a rare paradoxical entity where histologically benign tumor spreads to regional and distant sites (bone 21.88%, cervical lymph nodes 20.31%), typically after multiple recurrences with an average time to metastasis of 198 months 7
  • Among MPA patients with follow-up, 52.7% were alive and 8.4% died from disease 7
  • Carcinoma ex-pleomorphic adenoma occurs in high-grade malignancies with over 20% rate of clinically positive nodal involvement at presentation 8

Treatment Principles

  • Surgical excision with adequate margins is the preferred treatment 1
  • For benign or low-grade tumors in the superficial lobe, partial superficial parotidectomy with facial nerve preservation is appropriate per ASCO guidelines 5
  • Less extensive surgery (partial and superficial parotidectomies) has increased significantly from 1976 to 2022, while total parotidectomies have decreased 9
  • Facial nerve preservation is recommended when preoperative function is intact and a dissection plane can be created between tumor and nerve 5
  • Complete excision with adequate free margins is critical, as narrow margins (≤5mm) show excellent disease control in absence of adverse features for low/intermediate-grade tumors 5

Epidemiological Trends

  • The adjusted incidence in Olmsted County, Minnesota increased from 2.50 per 100,000 person-years (1976-1979) to 5.73 per 100,000 person-years (2020-2022) 9
  • The percentage of patients presenting with incidental imaging findings has increased, as has the median age at diagnosis (from 45 to 51 years) 9

References

Research

"Pleomorphic adenoma in salivary glands: Insights from a 100-patient analysis".

Journal of oral and maxillofacial pathology : JOMFP, 2024

Guideline

Parotidectomy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Metastatic Pleomorphic Adenoma: A Systematic Review.

Head and neck pathology, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tracking Pleomorphic Adenoma Incidence Trends Over 47 Years: A Population-Based Study.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.